Network pharmacology to unveil the blood components and mechanisms of Tongmai Yangxin Pills in treating elderly coronary heart disease
This study builds a bridge connecting TMYXP blood components and its confirmed clinical efficacy, identifies a series of anti-CHD lead compounds, and analyzes their possible mechanisms for treating CHD. The research strategy of this study has the potential to promote the modernization and transformation of TCM and promote the drug development.
Authors
- Peng Zeng (ORCID: https://orcid.org/0000-0002-6605-4736)
- Sijie Tan (ORCID: https://orcid.org/0000-0002-8389-7372)
- Jie Lin (ORCID: https://orcid.org/0000-0002-7059-0400)
- Chaohui Li (ORCID: https://orcid.org/0000-0001-7893-9665)
- Shanshan Zhu (ORCID: https://orcid.org/0000-0001-5464-4969)
- Yi-Zhi Yan (ORCID: https://orcid.org/0000-0003-2787-4819)
- Y. Zhang (ORCID: https://orcid.org/0009-0006-5186-9234)
Institutions
- University of South China (CN)
Publication Details
- Journal
- Frontiers in Cardiovascular Medicine
- Published
- 2025-02-13
- DOI
- https://doi.org/10.3389/fcvm.2025.1475546
- Citations
- 3
- Primary Topic
- Pharmacological Effects of Natural Compounds
- Type
- article
- Field-Weighted Citation Impact
- 4.67